Annual report pursuant to Section 13 and 15(d)

SEGMENTS (Details)

v3.22.1
SEGMENTS (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
Facility
Dec. 31, 2020
USD ($)
Segment Reporting Information [Abstract]    
Number of plasma collection facilities under development | Facility 10  
Number of operational collection plasma facilities | Facility 6  
Number of FDA-licensed plasma collection facilities | Facility 5  
Number of FDA-licensed plasma collection facilities received approval from Korean Ministry of Food and Drug Safety | Facility 1  
Revenues $ 80,942,625 $ 42,219,783
Cost of product revenue 79,769,341 61,291,426
Loss from operations (58,373,741) (64,914,877)
Interest and other expense, net (13,273,877) (11,825,468)
Gain (loss) on extinguishment of debt 0 991,797
Net loss (71,647,618) (75,748,548)
Capital expenditures 13,511,258 12,726,680
Depreciation and amortization expense 5,495,502 3,942,292
Total assets 276,252,724 207,673,394
Corporate [Member]    
Segment Reporting Information [Abstract]    
Revenues 142,834 142,834
Cost of product revenue 0 0
Loss from operations (17,024,068) (13,599,353)
Interest and other expense, net (13,050,164) (10,834,063)
Gain (loss) on extinguishment of debt   991,797
Net loss (30,074,232) (23,441,619)
Capital expenditures 0 0
Depreciation and amortization expense 5,334 9,193
Total assets 43,180,014 53,662,429
Operating Segments [Member] | ADMA BioManufacturing [Member]    
Segment Reporting Information [Abstract]    
Revenues 74,935,528 36,673,287
Cost of product revenue 74,124,999 55,908,696
Loss from operations (29,293,309) (46,904,634)
Interest and other expense, net (218,053) (984,017)
Gain (loss) on extinguishment of debt   0
Net loss (29,511,362) (47,888,651)
Capital expenditures 4,876,983 7,579,437
Depreciation and amortization expense 4,217,771 3,341,506
Total assets 208,391,019 140,908,957
Operating Segments [Member] | Plasma Collection Centers [Member]    
Segment Reporting Information [Abstract]    
Revenues 5,864,263 5,403,662
Cost of product revenue 5,644,342 5,382,730
Loss from operations (12,056,364) (4,410,890)
Interest and other expense, net (5,660) (7,388)
Gain (loss) on extinguishment of debt   0
Net loss (12,062,024) (4,418,278)
Capital expenditures 8,634,275 5,147,243
Depreciation and amortization expense 1,272,397 591,593
Total assets $ 24,681,691 $ 13,102,008